Floatz logo

FLUDEOXYGLUCOSE

Prostate Adenocarcinoma

Massachusetts General HospitalSmall moleculePhase 2/3Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
73/ 100

Competitive context

53 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Degarelix
Canadian Cancer Trials Group
Phase 3BB
LEUPROLIDE
Mayo Clinic
Phase 3BB
Zoladex
CancerCare Manitoba
Phase 3BB
Flutamide
NRG Oncology
Phase 3BB
Psma-Hbed-Cc
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

FLUDEOXYGLUCOSE is also rated in:

Recurrent Adult Brain TumorDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →